등온 핵산 증폭 기술 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 기술별(NASBA, HDA, LAMP, SDA, SDA, SPIA, NEAR), 용도별, 최종 용도별, 지역별, 부문별 예측(2023-2030년)

Isothermal Nucleic Acid Amplification Technology Market Growth & Trends

The global isothermal nucleic acid amplification technology market size is expected to reach USD 10,698.6 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.3% from 2023 to 2030 A significant rise in awareness regarding the rapid testing and early detection of chronic and infectious diseases is expected to be a significant factor driving the market growth. Furthermore, the global growth in the prevalence of HIV, hepatitis, and sexually transmitted diseases, as well as the rise in adoption of INAAT for the diagnosis of such diseases, is anticipated to drive market growth.

INAAT offers a more sensitive, accurate, and rapid alternative to traditional methods, such as culture-based identification, for the diagnosis of infectious diseases. Similarly, INAAT techniques require minimal resources and are used without the need for thermal cyclers, which significantly improves the portability of such techniques. Moreover, isothermal amplification involves the use of less expensive procedures and equipment, which can fuel its adoption in developing countries. In particular, regions such as the Asia Pacific and Africa, that have recently witnessed epidemics of infectious diseases, such as Zika virus, tuberculosis, and influenza, present significant opportunities for market expansion.

To address the growing demand for INAAT offerings, key players are expanding their product portfolio by the launch of advanced reagents for the latest INAAT products. For instance, in March 2022, Thermo Fisher Scientific, Inc. launched its Invitrogen Super Script IV RT-LAMP Master Mix, intended for the detection of various viral pathogens. Such product launches are favoring market growth by increasing the utility of INAAT techniques for a broad range of applications.

Furthermore, COVID-19 has positively affected the market growth by increasing demand for the rapid and accurate testing alternatives used for the detection of the SARS-CoV-2 virus. Several key players have developed new INAAT-based COVID-19 testing products and have secured emergency use approvals for such products from the U.S. FDA. For instance, commercially available products in this domain include Grifols Diagnostic Solutions Inc.'s Procleix SARS-CoV-2 assay and Lucira Health, Inc.'s Lucira CHECK-IT COVID-19 test kit. Such strategic initiatives fueled by COVID-19 are likely to provide a significant stimulus to market growth in the near future.

Isothermal Nucleic Acid Amplification Technology Market Report Highlights

• By product, the reagents segment accounted for the largest market share in 2022 due to the widespread availability of thermo stable polymerases, and increasing demand for cost-effective diagnostic alternatives such as INAAT products
• Loop-mediated isothermal amplification (LAMP) technology accounted for the largest share of 16.10% in 2022 as the technique allows for the use of multiple modes of detection and has the ability to detect a broad range of RNA and DNA targets
• By application, infectious disease diagnostics held the largest share of 35.25% in 2022. This can be attributed to the rising prevalence of infectious disease, globally, and promising alternatives offered by INAAT technologies over PCR-based techniques
• North America held a share of 42.68% and dominated the global market in 2022, due to the rapid growth in the healthcare sector and the presence of key players such as Thermo Fisher Scientific, Inc., Quidel Corporation, Meridian Bioscience, Inc., and others within the region
• Hospitals end-use segment held the largest market share of 40.13% in 2022 due to the increasing adoption of INAAT techniques for rapid diagnostics and increasing global healthcare expenditure

Table of Contents

Chapter 1. Methodology And Scope

• 1.1 Market Segmentation And Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Test Segment
    • 1.1.1.2 Service Provider Segment
    • 1.1.1.3 Application Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation And Scope
• 3.2. Market Lineage Outlook
  • 3.2.1 Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends And Outlook
• 3.4. Market Dynamics
  • 3.4.1 Increasing Incidences Of Chronic Diseases And Rise In The Aging Population Across The Globe
  • 3.4.2 Upsurge In The Molecular Diagnostics Market
  • 3.4.3 Rise In Demand For Low Cost And Effective Diagnostics Procedures
  • 3.4.4 Increase In The Available Disposable Income In The Developing Economies
  • 3.4.5 Increase In The Adoption Of Inaat Over Pcr Is Boosting The Market
  • 3.4.6 Rise In The Miniaturization Of Nucleic Acid-Based Diagnostics
• 3.5. Market Restraint Analysis
  • 3.5.1 Stringent Regulatory Framework
  • 3.5.2 Lack Of Awareness Over New Diagnostics Technologies
• 3.6. Business Environment Analysis
  • 3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis
• 3.7. Covid-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. Isothermal Nucleic Acid Amplification Technology Market: Product Movement Analysis
• 4.2. Instruments
  • 4.2.1 Instruments Market, 2018 - 2030 (USD Million)
• 4.3. Kits & Reagents
  • 4.3.1 Kits & Reagents Market, 2018 - 2030 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Isothermal Nucleic Acid Amplification Technology Market: Technology Movement Analysis
• 5.2. NASBA
  • 5.2.1 NASBA Market, 2018 - 2030 (USD Million)
• 5.3. HDA
  • 5.3.1 HDA Market, 2018 - 2030 (USD Million)
• 5.4. LA MP
  • 5.4.1 LA MP Market, 2018 - 2030 (USD Million)
• 5.5. SDA
  • 5.5.1 SDA Market, 2018 - 2030 (USD Million)
• 5.6. SPIA
  • 5.6.1 SPIA Market, 2018 - 2030 (USD Million)
• 5.7. NEAR
  • 5.7.1. NEAR Market, 2018 - 2030 (USD Million)
• 5.8. TMA
  • 5.8.1. TMA Market, 2018 - 2030 (USD Million)
• 5.9. RCA
  • 5.9.1 RCA Market, 2018 - 2030 (USD Million)
• 5.10. RPA
  • 5.10.1 RPA Market, 2018 - 2030 (USD Million)
• 5.11. SMAP2
  • 5.11.1 SMAP2 Market, 2018 - 2030 (USD Million)
• 5.12. Others
  • 5.12.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Isothermal Nucleic Acid Amplification Market: Application Movement Analysis
• 6.2. Blood Screening
  • 6.2.1 Blood Screening Market, 2018 - 2030 (USD Million)
• 6.3. Infectious Disease Diagnosis
  • 6.3.1 Infectious Disease Diagnosis Market, 2018 - 2030 (USD Million)
• 6.4. Cancer
  • 6.4.1. Cancer Market, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 7. End-Use Business Analysis

• 7.1. Isothermal Nucleic Acid Amplification Market: End-Use Movement Analysis
• 7.2. Hospital
  • 7.2.1 Hospital Market, 2018 - 2030 (USD Million)
• 7.3. Central And Reference Laboratories
  • 7.3.1 Central And Reference Laboratories Market, 2018 - 2030 (USD Million)
• 7.4. Others
  • 7.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Isothermal Nucleic Acid Amplification Technology Market: Regional Movement Analysis, 2022 & 2030
• 8.2. North America
  • 8.2.1 North America Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.2.2 U.S.
    • 8.2.1.1. Key Country Dynamics
    • 8.2.1.2. Competitive Scenario
    • 8.2.1.3. Prevalence Insights
    • 8.2.1.4. Regulatory Framework
    • 8.2.1.5. U.S. Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.2.3 Canada
    • 8.2.3.1 Key Country Dynamics
    • 8.2.3.2 Competitive Scenario
    • 8.2.3.3 Prevalence Insights
    • 8.2.3.4 Regulatory Framework
    • 8.2.3.5 Canada Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1 Europe Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2 Uk
    • 8.3.2.1 Key Country Dynamics
    • 8.3.2.2 Competitive Scenario
    • 8.3.2.3 Prevalence Insights
    • 8.3.2.4 Regulatory Framework
    • 8.3.2.5 Uk Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.3.3 Germany
    • 8.3.3.1 Key Country Dynamics
    • 8.3.3.2 Competitive Scenario
    • 8.3.3.3 Prevalence Insights
    • 8.3.3.4 Regulatory Framework
    • 8.3.3.5 Germany Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.3.4 France
    • 8.3.4.1 Key Country Dynamics
    • 8.3.4.2 Competitive Scenario
    • 8.3.4.3 Prevalence Insights
    • 8.3.4.4 Regulatory Framework
    • 8.3.4.5 France Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.3.5 Italy
    • 8.3.5.1 Key Country Dynamics
    • 8.3.5.2 Competitive Scenario
    • 8.3.5.3 Prevalence Insights
    • 8.3.5.4 Regulatory Framework
    • 8.3.5.5 Italy Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.3.6 Spain
    • 8.3.6.1 Key Country Dynamics
    • 8.3.6.2 Competitive Scenario
    • 8.3.6.3 Prevalence Insights
    • 8.3.6.4 Regulatory Framework
    • 8.3.6.5 Spain Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.3.7 Denmark
    • 8.3.7.1 Key Country Dynamics
    • 8.3.7.2 Competitive Scenario
    • 8.3.7.3 Prevalence Insights
    • 8.3.7.4 Regulatory Framework
    • 8.3.7.5 Denmark Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.3.8 Sweden
    • 8.3.8.1 Key Country Dynamics
    • 8.3.8.2 Competitive Scenario
    • 8.3.8.3 Prevalence Insights
    • 8.3.8.4 Regulatory Framework
    • 8.3.8.5 Sweden Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.3.9 Norway
    • 8.3.9.1 Key Country Dynamics
    • 8.3.9.2 Competitive Scenario
    • 8.3.9.3 Prevalence Insights
    • 8.3.9.4 Regulatory Framework
    • 8.3.9.5 Norway Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1 Asia Pacific Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2 Japan
    • 8.4.2.1 Key Country Dynamics
    • 8.4.2.2 Competitive Scenario
    • 8.4.2.3 Prevalence Insights
    • 8.4.2.4 Regulatory Framework
    • 8.4.2.5 Japan Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3 China
    • 8.4.3.1 Key Country Dynamics
    • 8.4.3.2 Competitive Scenario
    • 8.4.3.3 Prevalence Insights
    • 8.4.3.4 Regulatory Framework
    • 8.4.3.5 China Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4 India
    • 8.4.4.1 Key Country Dynamics
    • 8.4.4.2 Competitive Scenario
    • 8.4.4.3 Prevalence Insights
    • 8.4.4.4 Regulatory Framework
    • 8.4.4.5 India Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.5 Australia
    • 8.4.5.1 Key Country Dynamics
    • 8.4.5.2 Competitive Scenario
    • 8.4.5.3 Prevalence Insights
    • 8.4.5.4 Regulatory Framework
    • 8.4.5.5 Australia Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.6 Thailand
    • 8.4.6.1 Key Country Dynamics
    • 8.4.6.2 Competitive Scenario
    • 8.4.6.3 Prevalence Insights
    • 8.4.6.4 Regulatory Framework
    • 8.4.6.5 Thailand Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.7 South Korea
    • 8.4.7.1 Key Country Dynamics
    • 8.4.7.2 Competitive Scenario
    • 8.4.7.3 Prevalence Insights
    • 8.4.7.4 Regulatory Framework
    • 8.4.7.5 South Korea Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1 Latin America Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2 Brazil
    • 8.5.2.1 Key Country Dynamics
    • 8.5.2.2 Competitive Scenario
    • 8.5.2.3 Prevalence Insights
    • 8.5.2.4 Regulatory Framework
    • 8.5.2.5 Brazil Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3 Mexico
    • 8.5.3.1 Key Country Dynamics
    • 8.5.3.2 Competitive Scenario
    • 8.5.3.3 Prevalence Insights
    • 8.5.3.4 Regulatory Framework
    • 8.5.3.5 Mexico Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4 Argentina
    • 8.5.4.1 Key Country Dynamics
    • 8.5.4.2 Competitive Scenario
    • 8.5.4.3 Prevalence Insights
    • 8.5.4.4 Regulatory Framework
    • 8.5.4.5 Argentina Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.6. Middle East & Africa
  • 8.6.1 Middle East & Africa Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2 South Africa
    • 8.6.2.1 Key Country Dynamics
    • 8.6.2.2 Competitive Scenario
    • 8.6.2.3 Prevalence Insights
    • 8.6.2.4 Regulatory Framework
    • 8.6.2.5 South Africa Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3 Saudi Arabia
    • 8.6.3.1 Key Country Dynamics
    • 8.6.3.2 Competitive Scenario
    • 8.6.3.3 Prevalence Insights
    • 8.6.3.4 Regulatory Framework
    • 8.6.3.5 Saudi Arabia Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4 UAE
    • 8.6.4.1 Key Country Dynamics
    • 8.6.4.2 Competitive Scenario
    • 8.6.4.3 Prevalence Insights
    • 8.6.4.4 Regulatory Framework
    • 8.6.4.5 UAE Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5 Kuwait
    • 8.6.5.1 Key Country Dynamics
    • 8.6.5.2 Competitive Scenario
    • 8.6.5.3 Prevalence Insights
    • 8.6.5.4 Regulatory Framework
    • 8.6.5.5 Kuwait Isothermal Nucleic Acid Amplification Technology Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1 New Product Launch
  • 9.2.2 Partnerships
  • 9.2.3 Acquisition
  • 9.2.4. Collaboration
  • 9.2.5 Funding
• 9.3. Key Company Market Share Analysis, 2022
• 9.4. Company Profiles
  • 9.4.1 Alere, Inc.
    • 9.4.1.1 Company Overview
    • 9.4.1.2 Financial Performance
    • 9.4.1.3 Product Benchmarking
    • 9.4.1.4 Strategic Initiatives
  • 9.4.2 Biomerieux Sa
    • 9.4.2.1 Company Overview
    • 9.4.2.2 Financial Performance
    • 9.4.2.3 Product Benchmarking
    • 9.4.2.4 Strategic Initiatives
  • 9.4.3 Eiken Chemical Co. Ltd
    • 9.4.3.1 Company Overview
    • 9.4.3.2 Financial Performance
    • 9.4.3.3 Product Benchmarking
    • 9.4.3.4 Strategic Initiatives
  • 9.4.4 Hologic Inc.(Gen-Probe)
    • 9.4.4.1 Company Overview
    • 9.4.4.2 Financial Performance
    • 9.4.4.3 Product Benchmarking
    • 9.4.4.4 Strategic Initiatives
  • 9.4.5 Lucigen
    • 9.4.5.1 Company Overview
    • 9.4.5.2 Financial Performance
    • 9.4.5.3 Product Benchmarking
    • 9.4.5.4 Strategic Initiatives
  • 9.4.6 Meridian Bioscience, Inc.
    • 9.4.6.1 Company Overview
    • 9.4.6.2 Financial Performance
    • 9.4.6.3 Product Benchmarking
    • 9.4.6.4 Strategic Initiatives
  • 9.4.7 Ustar Biotechnologies Ltd.
    • 9.4.7.1 Company Overview
    • 9.4.7.2 Financial Performance
    • 9.4.7.3 Product Benchmarking
    • 9.4.7.4 Strategic Initiatives
  • 9.4.8 Qiagen
    • 9.4.8.1 Company Overview
    • 9.4.8.2 Financial Performance
    • 9.4.8.3 Product Benchmarking
    • 9.4.8.4 Strategic Initiatives
  • 9.4.9 Quidel Corporation
    • 9.4.9.1 Company Overview
    • 9.4.9.2 Financial Performance
    • 9.4.9.3 Product Benchmarking
    • 9.4.9.4 Strategic Initiatives
  • 9.4.10 Thermo Fisher Scientific, Inc.
    • 9.4.10.1 Company Overview
    • 9.4.10.2 Financial Performance
    • 9.4.10.3 Product Benchmarking
    • 9.4.10.4 Strategic Initiatives
  • 9.4.11 Bd (Becton, Dickinson & Company)
    • 9.4.11.1 Company Overview
    • 9.4.11.2 Financial Performance
    • 9.4.11.3 Product Benchmarking
    • 9.4.11.4 Strategic Initiatives
  • 9.4.12 Optigene Limited
    • 9.4.12.1 Company Overview
    • 9.4.12.2 Financial Performance
    • 9.4.12.3 Product Benchmarking
    • 9.4.12.4 Strategic Initiatives